Oxygen and pulmonary arterial hypertension: effects, mechanisms, and therapeutic benefits.

Abstract

Oxygen is a pulmonary vasodilator. Although treatment of pulmonary arterial hypertension (PAH) is focused on pulmonary vasodilation, treatment guidelines do not recommend O2 therapy for patients unless they develop hypoxaemia. These guidelines point to a lack of evidence of benefit of O2 therapy from randomized controlled trials (RCTs) and to evidence of lack of benefit in a single RCT involving patients with Eisenmenger syndrome. These guidelines did not identify major limitations with the Eisenmenger study or consider other evidence of therapeutic benefit. Recent advances in mechanistic understanding of O2 effects on pulmonary vascular tone, along with substantial evidence of acute effects of O2 in PAH patients, challenge the view that benefits of O2 arise only through correction of hypoxaemia. Evidence presented in this review shows that O2 acts as a pulmonary vasodilator in patients who are normoxaemic; that this probably involves an alveolar mechanism in addition to a blood-borne (oxyhaemoglobin) mechanism; and that therapeutic benefit of O2 does not depend on arterial O2 levels. This suggests that O2 has potential therapeutic benefit for all patients with PAH. Clinical guidelines and practice related to O2 therapy need to be reassessed, and further research is needed.

• Authors: Simon Green, Deidre Stuart
• Journal: European journal of preventive cardiology (Eur J Prev Cardiol) Vol. 28 Issue 1 Pg. 127-136 (03 23 2021) ISSN: 2047-4881 [Electronic] England
• PMID: 33623970 (Publication Type: Journal Article, Review)
• Copyright: Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: [email protected].

Chemical References

• Vasodilator Agents
• Oxygen

Topics

• Humans
• Hypertension, Pulmonary (diagnosis, drug therapy)
• Oxygen
• Oxygen Inhalation Therapy
• Pulmonary Arterial Hypertension
• Vasodilator Agents